CGAS and neoplasm: Nevertheless, Cgas KO in Hepa1-6 cells completely abrogated Cgas upregulation induced by VC treatment and in tumors derived from cGAS KO cells, the combination of VC and anti-PD-L1 had no obvious changes in tumor burdens as compared to single VC or anti-PD-L1 therapy (Fig. 10f–h).